Overview of approved and upcoming vaccines for SARS-CoV-2: a living review
The rapid design and implementation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is testament to a successfully coordinated global research effort. While employing a variety of different technologies, some of which have been used for the first time, all approved vaccines...
| Hauptverfasser: | , , , , , |
|---|---|
| Weitere Verfasser: | |
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
Oxford University Press
2021
|
| _version_ | 1826290953097314304 |
|---|---|
| author | Alderson, J Batchelor, V O'Hanlon, M Cifuentes, L Richter, FC Kopycinski, J |
| author2 | Oxford-Cardiff COVID-19 Literature Consortium |
| author_facet | Oxford-Cardiff COVID-19 Literature Consortium Alderson, J Batchelor, V O'Hanlon, M Cifuentes, L Richter, FC Kopycinski, J |
| author_sort | Alderson, J |
| collection | OXFORD |
| description | The rapid design and implementation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is testament to a successfully coordinated global research effort. While employing a variety of different technologies, some of which have been used for the first time, all approved vaccines demonstrate high levels of efficacy with excellent safety profiles. Despite this, there remains an urgent global demand for coronavirus disease 2019 vaccines that require further candidates to pass phase 3 clinical trials. In the expectation of SARS-CoV-2 becoming endemic, researchers are looking to adjust the vaccine constructs to tackle emerging variants. In this review, we outline different platforms used for approved vaccines and summarize latest research data with regards to immunogenicity, dosing regimens and efficiency against emerging variants. |
| first_indexed | 2024-03-07T02:52:04Z |
| format | Journal article |
| id | oxford-uuid:ae031eab-b960-4c02-ab54-ec66d237584b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:52:04Z |
| publishDate | 2021 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:ae031eab-b960-4c02-ab54-ec66d237584b2022-03-27T03:39:47ZOverview of approved and upcoming vaccines for SARS-CoV-2: a living reviewJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ae031eab-b960-4c02-ab54-ec66d237584bEnglishSymplectic ElementsOxford University Press2021Alderson, JBatchelor, VO'Hanlon, MCifuentes, LRichter, FCKopycinski, JOxford-Cardiff COVID-19 Literature ConsortiumThe rapid design and implementation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is testament to a successfully coordinated global research effort. While employing a variety of different technologies, some of which have been used for the first time, all approved vaccines demonstrate high levels of efficacy with excellent safety profiles. Despite this, there remains an urgent global demand for coronavirus disease 2019 vaccines that require further candidates to pass phase 3 clinical trials. In the expectation of SARS-CoV-2 becoming endemic, researchers are looking to adjust the vaccine constructs to tackle emerging variants. In this review, we outline different platforms used for approved vaccines and summarize latest research data with regards to immunogenicity, dosing regimens and efficiency against emerging variants. |
| spellingShingle | Alderson, J Batchelor, V O'Hanlon, M Cifuentes, L Richter, FC Kopycinski, J Overview of approved and upcoming vaccines for SARS-CoV-2: a living review |
| title | Overview of approved and upcoming vaccines for SARS-CoV-2: a living review |
| title_full | Overview of approved and upcoming vaccines for SARS-CoV-2: a living review |
| title_fullStr | Overview of approved and upcoming vaccines for SARS-CoV-2: a living review |
| title_full_unstemmed | Overview of approved and upcoming vaccines for SARS-CoV-2: a living review |
| title_short | Overview of approved and upcoming vaccines for SARS-CoV-2: a living review |
| title_sort | overview of approved and upcoming vaccines for sars cov 2 a living review |
| work_keys_str_mv | AT aldersonj overviewofapprovedandupcomingvaccinesforsarscov2alivingreview AT batchelorv overviewofapprovedandupcomingvaccinesforsarscov2alivingreview AT ohanlonm overviewofapprovedandupcomingvaccinesforsarscov2alivingreview AT cifuentesl overviewofapprovedandupcomingvaccinesforsarscov2alivingreview AT richterfc overviewofapprovedandupcomingvaccinesforsarscov2alivingreview AT kopycinskij overviewofapprovedandupcomingvaccinesforsarscov2alivingreview |